Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zanubrutinib Combined With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in the Treatment of Newly Diagnosed Diffuse Large B-cell Lymphoma With p53 Protein Expression

Next Previous
Trial Profile

Zanubrutinib Combined With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in the Treatment of Newly Diagnosed Diffuse Large B-cell Lymphoma With p53 Protein Expression

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Vincristine (Primary) ; Zanubrutinib (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use

Most Recent Events

  • 13 Dec 2022 Results (n=46; From November 6, 2020 to July 20, 2022) assessing the response rate, progression free survival and safety of RCHOP regimen combined with zanubrutinib for the first-line treatment of DE-DLBCL patients, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
  • 13 Aug 2022 New trial record
  • 17 Jun 2022 Results presented at the 27th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top